Buy NAD+ Injection
Three products answer to the same search. They differ in who prepares the solution, and that is the only difference that matters.
Buy NAD+ injection as a search phrase and three genuinely different products come back: a supervised infusion in a clinic, a compounded preparation dispensed on a prescription, and a sealed vial of dry powder sold as research material.
They are not three prices for the same thing. They differ at one specific point in the sequence, the moment the material becomes a solution intended to enter a body, and that point is where every real risk on this page lives. This is research material sold for laboratory use, not for human consumption.
One clarification first: NAD+ is nicotinamide adenine dinucleotide, a coenzyme, not a peptide. There is no sequence to check, and it is sold by the gram rather than in the milligram quantities the compounds beside it come in.
Where the order actually gets placed
Ascension Peptides, NAD+
US-based and third-party tested. Enter the code on the payment step and the vial halves before you confirm.
Quoted per 100 mg because NAD+ is dosed in hundreds of milligrams, not the single milligrams a peptide vial holds. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Two batch certificates per lot
- Shipping free over $250
- Out the door same day if you order before 2pm CST
Everything here is research material for laboratory use, not for human consumption. Affiliate links, so we may earn a commission at no cost to you. Prices last checked August 20, 2026.
Three things get sold as "buy NAD+ injection"
| What you are buying | Who prepares the solution | What you can verify yourself | What it needs from you |
|---|---|---|---|
| Clinic IV infusion | Clinic staff, from a compounded preparation | Almost nothing, unless you ask directly | An appointment and a long block of time |
| Compounded vial or syringe on prescription | A 503A pharmacy or 503B outsourcing facility | The pharmacy name and, on request, its testing scope | A prescriber and a dispensing pharmacy |
| Research-use vial, 1,000 mg powder | Nobody. It ships dry and sealed | The batch certificate and every assay on it | Payment, and nothing else |
Read the second column rather than the price column. The clinic route hands preparation to someone qualified and hands you no visibility. The research-use route hands you complete visibility of the starting material and no preparation at all. Neither is strictly safer than the other, and the reason is that the two failure modes sit at different stages.
The stage where sterility is decided
Here is the part that reorders how most people think about this purchase.
Sterility is not decided at the syringe. It is largely decided upstream, at the grade of the powder that went into the process, because bacterial endotoxin is heat-stable. Endotoxin is a fragment of bacterial cell wall, not a living organism, so killing the bacteria does not remove it. Filtration and autoclaving that would deal with viable microbes leave it behind. If the starting material carries a heavy endotoxin load, that load is still there in the bag.
FDA wrote about exactly this, on this exact substance, in a notice with content current as of 30 October 2024. The agency said it was aware of compounders using food-grade nicotinamide adenine dinucleotide sold by repackagers to make intravenous products. Ingredients identified as food grade, it said, "are not suitable for compounding sterile drugs without appropriate processing, due to the high risk of contamination with microbes and endotoxins, which can harm patients".
Then the consequence, in the agency's own words: it had received adverse event reports following use of NAD+ injectable drugs, "including severe chills, shaking, vomiting and fatigue with some requiring medical treatment", and these reactions were "consistent with excessive levels of endotoxins".
Two details in that notice are easy to skim past and worth pausing on. The first is that FDA urged manufacturers and repackagers to clearly label ingredients intended for food or supplement use, which is an admission that the labelling has not always made the distinction obvious. The second is that the agency noted it had previously raised the same concern about dietary-ingredient glutathione used in sterile injectables. This is a known pattern, not a one-off.
Why the bag has the highest bar and the least visibility
An intravenous product goes straight into the bloodstream in volume, over hours. It is the format with the highest sterility requirement of the three, and it is also the format where the buyer sees the least.
You are handed a prepared bag. You do not see the bulk container it was drawn from, the grade printed on that container, the certificate that came with it, or whether an endotoxin result appears on that certificate at all. The clinic may know all of it. You will only find out by asking.
That asymmetry is the reason the phrase "buy NAD+ IV" deserves scepticism when it appears on a page selling directly to the public. A finished intravenous drug product is not something a research supplier can lawfully sell you, and a site offering one is either mislabelling a powder or doing something that should stop you cold.
Six hours is the format, not a bonus
The only published human study that infused NAD+ directly, rather than one of its precursors, is Grant and colleagues in Frontiers in Aging Neuroscience, 2019. It was a pilot study, and it ran the infusion for six hours while tracking NAD+ and its metabolites in plasma and urine. The authors reported no measurable change in plasma NAD+ or its metabolites until after the second hour.
That is why a clinic NAD+ drip is booked as most of a working day rather than a lunch break, and it is the practical difference between buying an infusion and buying a shot. It is a scheduling fact. The study measured where infused NAD+ went in the body, not whether it did anyone any good, and several authors were affiliated with a wellness centre and an NAD+ research company, which belongs in any reading of it.
Powder is not an injection
What ships from a research supplier is a sealed vial holding a gram of lyophilised NAD+ powder. Dry, stable at room temperature in transit, and sold for laboratory use.
It is not a prepared injection and the listing does not claim to be one. There is no reconstitution guidance on this page and there will not be, because giving it would be describing human use of a product that is not sold for human use. What belongs here is the purchasing consequence: a dry powder is the format where you can inspect the paperwork before anything else happens, and that inspection window closes the moment the vial is opened.
The sequence that follows delivery, in the order it actually happens: parcel arrives, vial is sealed and the batch number is legible, batch number is matched against the certificate published for that lot, the assay list on that certificate is read line by line, and the vial goes into cold storage. Every check worth doing sits before the last step.
The endotoxin line on the certificate
This is the criterion the whole cluster turns on, and it is one line on one document.
| What the certificate shows | What it proves | What it leaves open |
|---|---|---|
| HPLC purity | How much of the powder is the stated substance | Whether it is clean enough to inject |
| Mass spectrometry | That the substance is what the label says | Whether it is clean enough to inject |
| Bacterial endotoxins, LAL | The endotoxin load, the thing FDA linked to the reported reactions | Nothing on this axis. This is the answer |
| Sterility test | Absence of viable organisms in the tested sample | Endotoxin, which survives what kills organisms |
Identity and purity are the two assays every vendor publishes, because they are the two that make a product look good. Endotoxin is the one that answers the question FDA raised. A supplier that reports HPLC and mass spectrometry and nothing else has documented what the powder is and left the actual safety question unanswered.
So the question to put to any vendor, or to any clinic, is narrow enough to be answered in one sentence: is this pharmaceutical grade rather than food grade, and does the batch certificate report an endotoxin result. If the answer arrives as reassurance rather than as a document, you have your answer.
On the clinic side the equivalent question is which pharmacy or outsourcing facility supplies the preparation. That distinction has teeth, because FDA notes that state boards of pharmacy have primary responsibility for day-to-day oversight of state-licensed pharmacies, while facilities registered with FDA as outsourcing facilities are inspected by FDA on a risk-based schedule and are subject to increased quality standards. Those are two different oversight regimes behind the same bag.
Common questions
Common Concerns
Can you buy a ready-to-use NAD+ injection?expand_more
Where does sterility actually get decided?expand_more
What did FDA actually find about NAD+ injectables?expand_more
Is buying an NAD+ IV at a clinic safer than buying a vial?expand_more
Why does the bag take so long compared with a shot?expand_more
Keep exploring
The local clinic search covers what to ask before booking a chair. The legal position explains why the research-use route has no prescription step in it, and the price page compares one payment for a gram against a per-session clock.
Sources
- FDA: Reminds Compounders to Use Ingredients Suitable for Sterile Compounding
- FDA: Compounding and the FDA, Questions and Answers
- FDA: Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act
- A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD (Frontiers in Aging Neuroscience, 2019)